Treatment of Hemophilia A Patients With FVIII Inhibitors
This study is for men with Haemophilia A who have developed 'inhibitors' – meaning their bodies stop responding to standard treatments. It's a long-term observational study, not a test of a new drug, that aims to understand current approaches to managing this condition across different hospitals. Researchers want to see how various treatments, including existing ones and a newer treatment called emicizumab, are used. They'll also look at a treatment strategy called 'Immune Tolerance Induction' (ITI), which aims to remove inhibitors. The study will track patients for up to five years to gather information on how well these treatments work and if they are safe in the real world.
A colpo d'occhio
Di cosa tratta questo studio?
Imagine you have Haemophilia A, a condition where your blood doesn't clot properly because you're missing a special protein called Factor VIII. Usually, doctors can give you this missing protein to help your blood clot. However, sometimes, a person's body can develop 'inhibitors.' This means their immune system sees the Factor VIII treatment as something foreign and tries to fight it off, making the medicine stop working. This can lead to more bleeds and serious problems.
This study aims to understand how doctors currently manage Haemophilia A in men who have developed these inhibitors. It's like watching and learning from what's already happening in different clinics around the world, rather than testing a brand new medicine. The researchers are particularly interested in a treatment approach called 'Immune Tolerance Induction' (ITI), which involves giving Factor VIII over a long period to try and train the body to accept it. They also want to see how well treatments like emicizumab, which is a newer option, are being used alongside Factor VIII.
By observing how people are treated and how they respond over a period of up to five years, the study hopes to gather important information. This information will help doctors understand which treatment approaches are most effective and safe for men with Haemophilia A and inhibitors, ultimately leading to better care in the future.
Punti chiave
- The study observes how Haemophilia A with inhibitors is currently treated.
- It focuses on men whose Factor VIII treatment no longer works effectively.
- No new medicines are given; your current treatment will be recorded.
- Information will be collected for up to five years during your regular clinic visits.
- The goal is to help doctors understand the best ways to manage this complex condition.
Chi può essere idoneo?
This study is looking for men who have Haemophilia A and have developed 'inhibitors' to their usual treatment for blood clotting. These inhibitors mean their body no longer fully responds to Factor VIII medicine. You might be eligible if you've had inhibitors before, even if you've tried reducing them with a treatment called Immune Tolerance Induction (ITI) in the past and it didn't work.
The study is specifically interested in people who are currently undergoing ITI treatment using certain Factor VIII products (Nuwiq, Octanate, or Wilate). You could also be eligible if you're on these ITI treatments and also receiving other medicines like emicizumab or bypassing agents (aPCC or rFVIIa) to help manage bleeds.
To join, you or your parent/guardian must be able to understand the study information and agree to take part by signing a consent form. However, you can't join if you have any other bleeding disorder besides Haemophilia A, or if your medical records for a past period aren't detailed enough about your treatments and bleeds.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you a man diagnosed with Haemophilia A?
- Have you developed 'inhibitors' that stop your Factor VIII medicine from working well?
- Are you currently having treatment to try and get rid of the inhibitors, or using certain medicines like emicizumab?
- Are you able to understand the study information and sign a consent form (or your parent/guardian can)?
- Do you only have Haemophilia A, with no other bleeding disorders?
Cosa comporta la partecipazione?
If you join this study, you won't be given new or different medicines just for the study. Instead, the doctors will continue with your usual Haemophilia A treatment as they normally would. The study will simply observe and record information about the treatments you are already receiving. This includes details about your medication, any bleeding episodes you might have, and how well your treatments are working.
You will be placed into one of three groups based on the treatments your doctor chooses for you. You might switch groups if your treatment plan changes during the study. Researchers will follow your progress and collect information during your regular clinic visits. You will be observed for a maximum of five years. There are no extra tests or appointments required specifically for the study; all information will be gathered from your routine care.
Rischi e benefici potenziali
Luoghi (2)
- Arthur M. Blank HospitalCodice postale verificatoAtlanta, Stati Uniti· Reclutamento
- HZRM Hämophilie-Zentrum Rhein MainCodice postale verificatoMörfelden-Walldorf, Germany· Reclutamento
Domande comuni
What are 'inhibitors' in Haemophilia A?
Inhibitors are like antibodies your body makes that stop your usual Haemophilia A medicine (Factor VIII) from working properly.
Will I get new medicine in this study?
No, this study only observes the treatments your doctor has already chosen for you; you won't receive any new study medicines.
Per quanto tempo sarò nello studio?
You will be observed for up to a maximum of five years.
Is this a test of a new drug?
No, it's an observational study to learn how existing treatments for Haemophilia A with inhibitors are currently used and how well they work.
Posso abbandonare lo studio se cambio idea?
Yes, you can withdraw from the study at any time without affecting your medical care.
Come saperne di più
Robert Sidonio, MD, MSc
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.